Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report)’s stock price dropped 1.3% on Wednesday . The company traded as low as $0.40 and last traded at $0.41. Approximately 45,408 shares changed hands during trading, a decline of 93% from the average daily volume of 697,094 shares. The stock had previously closed at $0.41.
Altamira Therapeutics Trading Down 1.3 %
The firm has a fifty day moving average price of $0.49 and a 200-day moving average price of $0.84.
Altamira Therapeutics Company Profile
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Featured Articles
- Five stocks we like better than Altamira Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
